Answer : The major players operating in the Australia GLP-1 receptor agonist market are AstraZeneca PLC, Biocon, Eli Lilly and Co, Novo Nordisk A/S ADR, Sanofi SA, and Others
Jump to: What does UK prescribing guidance say
his fits for your business & your goals Given your direction (you run The Wellness Lounge in Anchorage, youre doing IV therapies, youre branching into peptides, youre interested in body-recomposition, fat vs fluid tracking, inflammation control, mobility recovery) here are some bespoke notes: AOD 9604 could slot nicely into a 12-week body-recomposition protocol (which you already are designing) as the fat-metabolism component, paired with your IV therapies, peptide stacks, training/movement protocols, inflammation support
Enjoy a bowl of oatmeal or whole wheat bread to start your day off supporting your GLP-1 hormone levels